Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antisense therapy in oncology: present situation].

D Morán González1, A Domínguez-Gil Hurlé

  • 1Servicio de Farmacia, Hospital Universitario de Salamanca. dmorang@usal.es

Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|November 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of the number of daily pills and doses on adherence to antiretroviral treatment: a 7-year study.

Journal of clinical pharmacy and therapeutics·2015
Same author

Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.

Current drug metabolism·2013
Same author

[Biosimilars: assessment of efficacy, safety and cost].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2010
Same author

[Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2010
Same author

[Prevalence and factors associated with preventable adverse drug events leading to hospital admission].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2006
Same author

[Medical gases, new medications].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2005

Antisense therapy offers a novel cancer treatment by blocking cancer-promoting genes. While showing short-term efficacy and safety in trials, long-term studies are needed to confirm its effectiveness and toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Antisense therapy presents a targeted approach to cancer treatment, distinct from traditional chemotherapy.
  • Gene regulation plays a critical role in cancer progression, making it a key target for novel therapies.

Purpose:

  • To review the significant aspects of antisense therapy as a novel therapeutic alternative in oncology.
  • To discuss the mechanism of action of antisense oligonucleotides in controlling cancer cell proliferation.

Summary:

  • Antisense therapy utilizes antisense oligonucleotides to specifically block the expression of genes driving cancer progression.
  • Clinical trials indicate promising short- to mid-term efficacy and safety profiles for this innovative treatment modality.
  • This approach aims to control cancer growth while minimizing harm to normal cells, potentially reducing side effects.

Related Experiment Videos

Impact:

  • Antisense therapy represents a promising molecular drug development for cancer treatment.
  • Further long-term studies are essential to fully establish the clinical effectiveness and comprehensive toxicological profile of antisense therapies.
  • This therapeutic strategy holds potential for a more targeted and less toxic cancer treatment paradigm.